Due to the elevated expression of HDAC family members in various malignant tumors and their diverse carcinogenic mechanisms, the U.S. Food and Drug Administration (FDA) has approved HDAC inhibitors (HDACIs) for treating T-cell lymphoma and multiple myeloma. The gene discussed is HDAC9; the disease is T-cell non-Hodgkin lymphoma.